EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Utilization of an optimized AlphaFold protein model for structure‐based design of a selective HDAC11 inhibitor with anti‐neuroblastoma activity

Fady Baselious, Sebastian Hilscher, Sven Hagemann, Sunita Tripathee, Dina Robaa, Cyril Barinka, Stefan Hüttelmaier, Mike Schutkowski, Wolfgang Sippl

Archiv der Pharmazie · 2024-10 · 357 (10)

DOI: 10.1002/ardp.202400486 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, online erschienen am 12.07.2024. Verfasst von Fady Baselious und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Institute of Pharmacy, Martin-Luther-University of Halle-Wittenberg, Halle (Saale), Germany. Hauptthemen laut MEDLINE: Antineoplastic Agents, Drug Design, Histone Deacetylase Inhibitors, Histone Deacetylases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Deutsche Forschungsgemeinschaft (DFG), CAS, Grant Agency of the Czech Republic.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AlphaFold is an artificial intelligence approach for predicting the three‐dimensional (3D) structures of proteins with atomic accuracy. One challenge that limits the use of AlphaFold models for drug discovery is the correct prediction of folding in the absence of ligands and cofactors, which compromises their direct use. We have previously described the optimization and use of the histone deacetylase 11 (HDAC11) AlphaFold model for the docking of selective inhibitors such as FT895 and SIS17. Based on the predicted binding mode of FT895 in the optimized HDAC11 AlphaFold model, a new scaffold for HDAC11 inhibitors was designed, and the resulting compounds were tested in vitro against various HDAC isoforms. Compound 5a proved to be the most active compound with an IC 50 of 365 nM and was able to selectively inhibit HDAC11. Furthermore, docking of 5a showed a binding mode comparable to FT895 but could not adopt any reasonable poses in other HDAC isoforms. We further supported the docking results with molecular dynamics simulations that confirmed the predicted binding mode. 5a also showed promising activity with an EC 50 of 3.6 µM on neuroblastoma cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsDrug DesignHistone Deacetylase InhibitorsHistone DeacetylasesNeuroblastomaHumansArtificial IntelligenceCell Line, TumorDose-Response Relationship, DrugMolecular Docking SimulationMolecular Dynamics SimulationMolecular StructureStructure-Activity Relationship

Stichwörter der Autor:innen

AlphaFoldHDAC11model optimizationmolecular dynamics simulationneuroblastoma

Substanzen

Antineoplastic AgentsHDAC11 protein, humanHistone Deacetylase InhibitorsHistone Deacetylases

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, Institute of Pharmacy, Martin-Luther-University of Halle-Wittenberg, Halle (Saale), Germany.
  • Institute of Molecular Medicine, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
  • Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Vestec, Czech Republic.
  • Charles Tanford Protein Center, Department of Enzymology, Institute of Biochemistry and Biotechnology, Martin-Luther-University of Halle-Wittenberg, Halle (Saale), Germany.

Förderung

  • Deutsche Forschungsgemeinschaft (DFG)
  • CAS
  • Grant Agency of the Czech Republic

Zitieren

APA

Baselious, F., Hilscher, S., Hagemann, S., Tripathee, S., Robaa, D., Barinka, C., Hüttelmaier, S., Schutkowski, M., & Sippl, W. (2024). Utilization of an optimized AlphaFold protein model for structure‐based design of a selective HDAC11 inhibitor with anti‐neuroblastoma activity. Archiv der Pharmazie, 357(10). https://doi.org/10.1002/ardp.202400486

Vancouver

Baselious F, Hilscher S, Hagemann S, Tripathee S, Robaa D, Barinka C, et al. Utilization of an optimized AlphaFold protein model for structure‐based design of a selective HDAC11 inhibitor with anti‐neuroblastoma activity. Archiv der Pharmazie. 2024;357(10). doi:10.1002/ardp.202400486

BibTeX
@article{Baselious2024,
  author = {Baselious, Fady and Hilscher, Sebastian and Hagemann, Sven and Tripathee, Sunita and Robaa, Dina and Barinka, Cyril and Hüttelmaier, Stefan and Schutkowski, Mike and Sippl, Wolfgang},
  title = {Utilization of an optimized AlphaFold protein model for structure‐based design of a selective HDAC11 inhibitor with anti‐neuroblastoma activity},
  journal = {Archiv der Pharmazie},
  year = {2024},
  volume = {357},
  number = {10},
  doi = {10.1002/ardp.202400486}
}
Kostenlos starten →